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Lentivectors (LVs) have attracted considerable interest for their
potential as a vaccine delivery vehicle. In this study, we evaluate
in mice a dendritic cell (DC)-directed LV system encoding the Gag
protein of human immunodeficiency virus (HIV) (LV-Gag) as a
potential vaccine for inducing an anti-HIV immune response. The
DC-directed specificity is achieved through pseudotyping the vec-
tor with an engineered Sindbis virus glycoprotein capable of
selectively binding to the DC-SIGN protein. A single immunization
by this vector induces a durable HIVGag-specific immune response.
We investigated the antigen-specific immunity and T-cell memory
generated by a prime/boost vaccine regimen delivered by either
successive LV-Gag injections or a DNA prime/LV-Gag boost proto-
col. We found that both prime/boost regimens significantly en-
hance cellular and humoral immune responses. Importantly, a
heterologous DNA prime/LV-Gag boost regimen results in superior
Gag-specific T-cell responses as compared with a DNA prime/
adenovector boost immunization. It induces not only a higher
magnitude response, as measured by Gag-specific tetramer anal-
ysis and intracellular IFN- staining, but also a better quality of
response evidenced by a wider mix of cytokines produced by the
Gag-specific CD8 and CD4 T cells. A boosting immunization with
LV-Gag also generates T cells reactive to a broader range of
Gag-derived epitopes. These results demonstrate that this DC-
directed LV immunization is a potent modality for eliciting anti-HIV
immune responses.
AIDS vaccine  human immunodeficiency virus  lentiviral vector 
T cell vaccine
Recombinant adenovirus-based vectors (rAd), used eitheralone or as a booster immunization after priming with a
DNA plasmid, are among the most potent viral vectors for
inducing human immunodeficiency virus (HIV)-specific T-cell
responses in animals and humans (1, 2). However, a phase 2b
trial that used recombinant adenovirus serotype 5 (rAd5) vectors
as the HIV vaccine carrier failed to show efficacy (3–6). This
trial result is consistent with a preclinical study in which a
rAd5-based vaccine expressing a simian immunodeficiency virus
(SIV) Gag antigen failed to lower setpoint viral loads after SIV
challenge of rhesus monkeys (7). A recent study by Barouch and
coworkers has shown that a heterologous prime/boost vaccine
regimen using a newly identified rAd26 vector could elicit a
strong and high quality immune response in non-human primates
(NHP), resulting in markedly reduced viral loads and decreased
AIDS-relatedmortality (8). This study highlights the importance
of exploring viral vector-based vaccine modalities for develop-
ment of an effective HIV vaccine.
Efficient antigen delivery to antigen-presenting cells (APCs)
and their subsequent presentation to stimulate virus-specific T
cells is vital for the success of a T-cell-based vaccine. Dendritic
cells (DCs) are the most powerful APCs to initiate and maintain
immune responses of T cells (9–11) and therefore become one
of the major target cells for the HIV vaccine development (12,
13). Immunization by adoptive transfer of autologous DCs
loaded in vitro with inactivated HIV particles induced anti-virus
immunity in animals (14–16) and humans (17, 18). However, this
is a labor-intensive, personalized medicine approach, which
limits its prospect as a vaccine design to deal with the worldwide
AIDS pandemic. A direct method is to target the delivery of HIV
immunogens to DCs in vivo (19, 20). Steinman and coworkers
reported a strategy to conjugate HIV Gag p24 and p41 onto an
antibody to DEC-205, a relatively DC-restricted surface protein,
as a means to load antigens into DCs in vivo for generating an
immune response (21, 22). Although with coadministration of
appropriate adjuvants, a strong Gag-specific CD4 T-cell re-
sponse was elicited (21), it remains a challenge for this antibody
fusion vaccine to evoke CD8 cytotoxic T cells, which are
essential for controlling HIV replication.
We have developed a DC-targeted, lentivector (LV)-based
system for delivery of genetic vaccines in vivo (23). LV is known
to be an efficient vehicle for genetic modification of DCs in vitro
(24), and direct injection with LV enveloped with glycoproteins
with broad tropism is able to induce CD8 T-cell responses
(25–30). To fully harness the immuno-stimulatory potency of
DCs and mitigate off-target effects, we synthesized a LV envel-
oped with a Sindbis virus-derived glycoprotein engineered to be
specific to the DC-specific surface protein DC-SIGN [also
known as CD209 (31, 32)] (23); DC-SIGN has also been explored
by others as the target receptor of DCs for protein antigen
delivery (20, 33). In our prior studies, we used ovalbumin (OVA)
as a model antigen and found that a single-round immunization
with this vector could result in substantial antigen-specific T-cell
and antibody response (23). In the present study, we show that
the significant HIV Gag-specific immune response can be elic-
ited by this DC-directed LV used alone or with other modalities.
Results
Immune Responses Generated by Various Routes of Vaccine Admin-
istration. We constructed a Gag-encoding lentiviral backbone
plasmid by insertion of Gag cDNA into FUW (34) downstream
of a human ubiquitin C promoter, a vector designated FUWGag
(Fig. 1A). LV encoding the Gag immunogen and pseudotyped
with the DC-directed envelope SVGmu was generated in 293T
cells by transient transfection with appropriate combinations of
various plasmids (see Materials and Methods) and is designated
LV-Gag. We first tested a range of vector doses [1.25 
10610  106 transduction units (TU)] for immunization of
naive mice through footpad injection and found that a dose of
5  106 TU generated the highest percentage of Gag-specific
CD8 T cells 2 weeks after vaccination. We then assessed the
immunogenic response to this vector dose via different admin-
istration routes. Naive mice were immunized with a single
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injection by the s.c. (s.c.), footpad (f.p.), intramuscular (i.m.), i.p.
(i.p.), or intradermal (i.d., at the base of tail) route. Gag-specific
T-cell responses were monitored by tetramer analysis and intra-
cellular cytokine staining (ICCS). The f.p. and i.d. injections
resulted in the strongest Gag-tetramer CD8 T-cell responses
(3%, Fig. 1B, left) 2 weeks postimmunization, consistent with
these being the best routes to target skin DCs. The i.p. injection
gave the lowest responses. When splenocytes harvested from
vaccinated animals were restimulated in vitro with the Gag-
dominant peptide (AMQMLKETI), a similar trend for the
pattern of IFN (IFN)- producing CD8 T cells was observed
(Fig. 1B, right).
HIV Gag-specific serum IgG and IgM could be detected 2
weeks postimmunization with the LV-Gag. The highest IgG
titers were obtained from the f.p., i.d., and s.c. routes (Fig. 1C,
left). Interestingly, the IgM titer showed a reverse trend, in which
f.p. and i.d. injections yielded lower IgM production (Fig. 1C,
right). This suggests that immunization through these two in-
jection routes yields a significant CD4 T-cell response, resulting
in efficient isotype switching to convert IgM into IgG. Because
of the superior response, the f.p. injection route was chosen for
the subsequent prime/boost and other functional studies.
Enhanced Gag-Specific Immunity by Prime/Boost Regimens. To fur-
ther characterize the efficacy of the LV-Gag immunization, four
cohorts of mice were injected with PBS, empty LV (lacking the
Gag transgene), bone marrow-derived DCs (BMDCs) loaded
with the HIV-1 Gag dominant peptide and matured with
lipopolysaccharide (LPS), or LV-Gag. Two weeks postinjection,
we assessed IFN--secreting CD8 T cells in freshly harvested
splenocytes restimulated in vitro with the Gag peptide for all of
the comparison groups. We observed that the LV-Gag-
immunized mice displayed a significant fraction of CD8 T cells
secreting IFN-, with a statistically significant difference (P 
0.01) when compared to the three comparison groups (Fig. 2A).
The fact that the empty vector was not different from the PBS
control suggests that the Gag-specific CD8 T cells elicited by
LV-Gag results from the delivery of the vector-encoded trans-
gene, rather than being elicited by Gag protein that might be
carried within the vector particles. In addition, no significant
level of epitope-specific responses was elicited by adoptive
transfer of in vitro-loaded DCs, indicating that DC-directed
delivery of Gag antigen by the LV in vivo is a much more potent
vaccination method.
We next explored the utility of the LV-Gag vector in prime/
boost settings. Three groups of mice received either one dose of
LV-Gag vector, a dose of LV-Gag vector prime followed by a
homologous LV-Gag vector boost, or a DNA prime followed by
a LV-Gag vector boost. Two weeks after the final injection,
tetramer-positive and IFN--producing CD8 T cells were quan-
tified by flow cytometry (Fig. 2B). Both assays showed an
enhanced anti-Gag CD8 T cells response in the prime/boost
animals compared to the single dose LV-Gag immunization
group. Splenocytes from the different groups of animals were
also cocultured with Gag peptide and then examined for IFN-
production by an ELISPOT assay (Fig. 2C). Obvious enhance-
ment of IFN- secretion was seen in the prime/boost groups, with
4- to 5-fold greater responses than for the single dose LV-Gag
mice. We further measured the titers of HIV Gag-specific IgG
and IgM antibodies in the sera from these animals and found that
sera from LV-Gag/LV-Gag mice and DNA/LV-Gag mice
showed higher responses to Gag protein than the single dose
LV-Gag mice (Fig. 2D). Collectively, our data demonstrate that
the DC-directed LV is an effective booster of responses initiated
by either DNA or LV itself, enhancing CD8 T-cell as well as
antibody responses.
Comparison of T-Cell Responses Elicited by Lentivector and Adenovec-
tor. We conducted experiments to compare DC-directed LV
with the extensively studied rAd5 for their ability to induce the
Gag-specific immune responses. Several groups of naive mice
were immunized with a DNA prime/LV-Gag boost, LV-Gag
prime/LV-Gag boost, or DNAprime/rAd5-Gag boost. Following
the last immunization, comparable frequencies of IFN--
producing and Gag-specific CD8 T cells were detected in
splenocytes of the prime/boost vaccine groups (Fig. 3A). Pre-
sumably due to the high rAd5 vaccine dose (1010 VP) used in this
study, we found that a single rAd5-Gag immunization was about
as good as the prime/boost regimens.
Kinetic analysis of the early responses to single immunization
showed that the magnitude of Gag-specific CD8 T-cell immu-
nity with LV-Gag immunization declined after week 2 to ap-
proximately 1% IFN--producing CD8 T cells by 4 weeks
postvaccination (Fig. 3B). In contrast, the primary response to
the rAd5-Gag vaccine reached a higher level at week 2, and active
T cells were continuously expanded through week 4 (Fig. 3B).
The memory phenotype of the Gag-specific CD8 T cells
elicited by different regimens was studied by scoring the memory
differentiation markers CD44 and CD62L. After gating on
Gag-tetramerCD8 T cells among splenocytes from LV-Gag-
vaccinated mice, approximately 30% of them exhibited the
central memory phenotype of CD44hiCD62L, which was higher
than the approximately 12% obtained from mice immunized
with the rAd5-Gag vector (Fig. 3C). The LV-Gag immunized
cells also displayed a discrete very high CD62L population
Fig. 1. Comparison of immune responses generated fromdifferent injection
routes after a single immunization. (A) Schematic representation of a lenti-
viral backbone construct encoding the full sequence of a HIV-1 subtype B Gag
antigen. R, U5, andU3are components of the long terminal repeat (LTR) and
U3 contains the self-inactivating deletion; SD: splicing donor; SA: splicing
acceptor;  and Gag: the encapsulation sequence; RRE: the Rev-responsive
element; Ubi: human ubiquitin-C promoter;WPRE: woodchuck hepatitis virus
posttranductional regulatory element. (B) Five groups of BALB/c mice were
immunized with 5 106 TU (Transduction Units) of LV-Gag by a s.c., footpad
(f.p.), intramuscular (i.m.), i.p., or intradermal (i.d.) injection route. Twoweeks
postimmunization, spleen cells were harvested and analyzed for the fre-
quency of Gag-specific CD8 T cells by H2-Kd-AMQMLKETI-PE tetramer and
CD44 staining. Spleen cells were also restimulated in vitro with the HIV-1 Gag
peptide (AMQMLKETI). Intracellular cytokine staining (ICCS) was performed
to assess the IFN- response. (C) Sera from different groups of mice were
harvested 2 weeks postimmunization. IgG and IgM antibody responses
againstHIV-1GagweredetectedbyELISA. Eachgroup consistedof threemice.









lacking in the rAd5-Gag immunized mice. This result suggests
that the DC-targeted LV is more potent than rAd5 for induction
of high quality memory T cells.
Multifunctional CD4 and CD8 T-Cell Responses Elicited by Lentivec-
tor.We examined the capacity of individual HIV-specific T cells
to produce multiple cytokines, a parameter which was shown to
correlate with a cell’s ability to protect against infection in
certain models (35). We selected the LV-Gag/LV-Gag, DNA/
LV-Gag, and DNA/rAd5-Gag immunization regimens for the
study because they were able to generate sufficiently high levels
of responses to allow a reliable multifunctionality analysis.
Splenocytes harvested from vaccinated animals were restimu-
lated with a pool of 123 overlapping peptides covering the entire
Gag protein. Intracellular cytokine levels were measured by
multiparameter flow cytometry to assess the ability of single cells
to produce various combinations of IFN-, interleukin (IL)-2
and tumor necrosis factor (TNF)-. As shown in Fig. 4A,
although the DNA/rAd5-Gag elicited CD4 T cells that were
single-positive for IFN-, IL-2, or TNF-, and double-positive
for IFN- and TNF-, there was no detectable level of these cells
that were IFN-IL-2, IL-2TNF-, or IFN-IL-2TNF-
. In contrast, both the LV-Gag/LV-Gag and DNA/LV-Gag
regimens generated substantial percentages of CD4 T cells that
were IFN-TNF-, IFN-/IL-2, and IL-2TNF-. Espe-
cially, the DNA/LV-Gag group induced a high frequency of
CD4 T cells secreting three cytokines simultaneously (6.4% of
the responding cells). The distribution of Gag-specific CD8 T
cells by various regimens showed the same pattern (Fig. 4A).
Compared with the DNA/rAd5-Gag immunization, a substan-
tially greater proportion of the LV-Gag/LV-Gag- or DNA/LV-
Gag-elicited CD8 T cells were able to secrete multiple cyto-
kines, with approximately 3% of responding cells from the
DNA/LV-Gag vaccine producing three cytokines. Interestingly,
we found that CD4 T cells were more multipotent than CD8
T cells. Examining the IL-2-secreting CD4 T cells, we see that
although the overall frequency of such cells was highest following
DNA/rAd5-Gag immunization, only a slight portion of them
secreted more than one cytokine (i.e., 2.8% of them are IL-
Fig. 2. DC-directed LV can effectively boost HIV-1 Gag-specific immune response. (A) BALB/c mice were immunized with PBS (F), BMDCs (1  106) loaded by
the HIV-1 Gag peptide (AMQMLKETI) (■), empty LV lacking the Gag transgene (5 106 TU) (Œ), or LV-Gag (5 106 TU) (). The immune responses of spleen cells
upon restimulation with the Gag dominant peptide were estimated by IFN- ICCS 2 weeks postinjection (*, P  0.01; **, P  0.001) (B–D) Four vaccine groups
received PBS, single immunization of LV-Gag (LV-Gag once), LV-Gag prime/LV-Gag boost (LV-Gag/LV-Gag), or DNA prime/LV-Gag boost (DNA/LV-Gag).
Splenocytes from vaccinated animals were analyzed for Gag-specific response by H2-Kd-AMQMLKETI-PE tetramer staining (B), IFN- ICCS (C), and mouse serum
ELISAs for IgG and IgM (D). The data shown are mean values of triplicates  SD.
Fig. 3. Comparison of magnitude, kinetics and memory responses of Gag-
specificCD8T cells after immunizationwithLV-Gagand rAd5-Gag. Sixgroups
of BALB/c mice received the following vaccination regimens: PBS, LV-Gag (LV,
5  106 TU), rAd5-Gag (rAd5, 1010 VP), LV-Gag prime/LV-Gag boost (LV/LV),
DNA prime/LV-Gag boost (DNA/LV), and DNA prime/rAd5-Gag boost (DNA/
rAd5). Vaccine-inducedHIVGag-specific immune responseswere analyzedby:
(A) percentage of IFN-- or Gag-tetramer-positive CD8 T cells (*, P  0.05;
**, P  0.005); (B) kinetics of the total frequency of IFN--producing CD8 T
cells of LV-Gag and rAd5-Gag groups on indicated time points after immuni-
zation; and (C) division of centralmemory (TCM, CD44highCD62L) and effector
memory (TEM, CD44highCD62L) CD8 T cells of LV-Gag (LV) and rAd5-Gag
(rAd5) groups by surface staining.
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2TNF-) (Fig. 4B). On the contrary, at least half of the
IL-2-secreting CD4 T cells from both DNA/LV-Gag and
LV-Gag/LV-Gag vaccination were multicytokine producers, and
a notable portion of them were able to generate three cytokines.
Thus, both the CD4 and CD8T cells induced by immunization
involving DC-directed LV were more polyfunctional than those
generated by the DNA/rAd5-Gag vaccine.
Breadth of T-Cell Responses Induced by Various Immunization Regi-
mens. To assess the breadth of the induced T-cell responses, we
generated a peptide matrix as shown in Fig. 5A (36). A library
of peptides covering the entire HIV-1 Gag protein was divided
into 23 pools named P1-P23, with each peptide present in two
independent pools. The splenocytes of mice immunized with
LV-Gag/LV-Gag, DNA/LV-Gag, and DNA/rAd5-Gag were
stimulated by one of the peptide pools, and then assayed by
IFN-ELISPOT. In contrast to the T cells fromDNA/rAd5-Gag
immunized mice, those from LV-Gag/LV-Gag mice responded
to many peptides. Taking an ELISPOT cut-off at 80 SFC (spot
forming cells)/0.1 million cells, mice immunized with LV-Gag/
LV-Gag responded to eight peptide pools (P4, P5, P6, P9, P10,
P15, P17, and P18) (Fig. 5 B and C), while the DNA/LV-Gag and
DNA/rAd5-Gag mice only vigorously responded to three pools
(P4, P5, and P17) (Fig. 5 B and C). We were able to verify the
response of LV-Gag/LV-Gag T cells to 11 individual peptides
derived from these responding eight peptide pools (Fig. S1).
However, when the DNA/rAd5-Gag did respond to a peptide
pool, its response was higher than that of the mice receiving
LV-Gag. There were 15 different peptide pools identified as
nonreactive (refers to the ELISPOT reading 20 SFC/0.1
million cells) to cells from the DNA/rAd5-Gag immunized mice.
However, none of the pools were found to be nonreactive for
either the LV-Gag/LV-Gag or DNA/LV-Gag induced T cells
(Fig. 5B). We also conducted an ICCS analysis of the LV-Gag/
LV-Gag splenocytes stimulated by two representative peptide
pools (P6 and P10) and found that the ratio of Gag-specific CD8
vs. CD4 T-cell responses for both pools was approximately 3:1
(Fig. S2). The above results indicate that the Gag-specific T cells
generated by LV-Gag-involved vaccination regimens (LV-Gag/
LV-Gag and DNA/LV-Gag) can recognize a broader range of
epitopes as compared to the T-cell response induced by the
DNA/rAd5-Gag strategy. The DNA/rAd5-Gag-immunized mice
gave a high total response but one much more focused on
immune-dominant determinants.
Fig. 4. Generation of multifunctional CD4 and CD8 responses by prime/
boost immunization regimens. Splenocytes of DNA/rAd5-Gag (DNA/rAd5),
LV-Gag/LV-Gag (LV/LV) and DNA/LV-Gag (DNA/LV) groups of BALB/c mice
were stimulated with the pooled HIV-1 Gag peptides (2.5 g/mL for each
peptide) for 6 h, and analyzed by an eight-color ICCS assay to assess: (A) the
fraction of total responding CD4 or CD8 T cells expressing each of the seven
possible combinations of IFN-, IL-2, and TNF-; and (B) the frequency and
proportionof respondingCD4 T cells expressing all three cytokines (IFN-IL-
2TNF-: 2), two cytokines (IFN-IL-2TNF-: 2; or IFN-
IL-2TNF-: 2), or one cytokine (IFN-IL-2TNF-: 2).
Fig. 5. Breadth of HIV-1 Gag-specific responses to LV-Gag-based vaccination. (A) A library of 123 15-mer peptides spanning the entire HIV-1 subtype B Gag
sequence was divided into 23 pools (P1–P23) as indicated by the peptidematrix table. (B and C) Spleen cells of DNA/rAd5-Gag, LV-Gag/LV-Gag, and DNA/LV-Gag
groups of BALB/c mice were harvested, stimulated with one of peptide pools for 18–24 h, and assayed by IFN- ELISPOT. Each group consisted of three mice.
Number of highly reactive peptide pools versus number of nonreactive peptide pools for each group of mice was summarized as shown in (B). The threshold for
defining a nonreactive peptide pool was based on the ELISPOT readout comparable with the control PBS group. A peptide pool was defined as highly reactive
when its stimulated response was 5 times higher than that of the control PBS reading and could be obviously detected by an ICCS assay.










We have previously shown that one can build a replication-
deficient LV that targets a gene of interest directly to DCs in an
animal to induce antigen-specific immune responses (23). In this
study, we examine a special case, the production of T cells and
antibodies against the Gag protein of HIV. This is of particular
interest because attempts to make a vaccine against HIV have
failed thus far and a new and more effective vector system is
needed (5, 6). When this vector was used to deliver Gag
immunogen (LV-Gag), a significant quantity of Gag-specific
CD8 T cells could be detected upon a single injection. We
performed a direct comparison of the LV-Gag with rAd5-Gag
with the respect to magnitude, kinetics and the memory nature
of the induced cellular immune response. A single round im-
munization of rAd5-Gag induced a stronger immunity than
LV-Gag at the chosen doses. The time-course measurement
showed that LV-Gag resembled a usual immune response of
expansion and contraction, but rAd5-Gag provoked a persistent
response. This persistent immunization of rAd-Gag vector might
stem from the continuously active transcription of adenovirus
vector at the site of injection (37) and could present a challenge
for generating high quality memory T cells (2, 5). This unusually
prolonged response of rAd5-Gag can compromise its utilities for
repeated immunization [such a protocol was used by Merck’s
STEP trial (3, 4)] because the sustained APCs and neutralizing
antibodies may inhibit responses from further homologous vac-
cination. As compared with the rAd5-Gag vector, LV-Gag
induced a greater percentage of Gag-specific memory T cells
that were of the central memory phenotype (TCM:
CD44highCD62L).
Heterologous prime/boost strategies have been well-studied
for AIDS vaccines, especially with a rAd5-based vector (38, 39).
Unlike the adenoviral vector, the DC-directed LV is less likely
to be restricted by the preexisting immunity, thus we tested its
application for both homologous and heterologous vaccination
regimens. We demonstrated that the DNA/LV-Gag as well as
LV-Gag/LV-Gag displayed a remarkable enhancement of vac-
cine efficacy for generation of HIV-specific T-cell and antibody
responses. Although generation of a robust CD8 T-cell re-
sponse is one requirement for a HIV vaccine, the magnitude
itself is not necessarily predictive of a superior control of HIV
infection in many individuals (40). Therefore, we further inves-
tigated the functional potency and breadth of LV-Gag-induced
T-cell responses. The CD8 T cells from the DNA/rAd5-Gag
regimen were primarily IFN-, TNF-, and IFN-TNF-
cells, with few of them secreting IL-2. The ability of CD8 T cells
to generate IL-2 could be significant because it should allow
them to survive and expand (41). Moreover, the central memory
CD8 T cells which home to lymphoid organs are thought to
produce IL-2, while the effector counterparts are restricted to
peripheral tissues and primarily secrete IFN- (42). Promisingly,
our data indicate that there is a significant portion of HIV-
specific CD8 T cells generated by either DNA/LV-Gag or
LV-Gag/LV-Gag that are IL-2 producers. Notably, approxi-
mately 3% of the cytokine-producing DNA/LV-Gag-induced
CD8 T cells produced three cytokines.
CD4 T cells, especially the polyfunctional ones, are of great
importance to vaccine responses (43). Consistent with the results
of Sun et al. (42), we observed that IFN- and TNF- production
dominated the CD4 T-cell population induced by DNA/rAd5-
Gag immunization. The functional profiles of Gag-specific
CD4 T cells elicited by DNA/LV-Gag and LV-Gag/LV-Gag
were different from that of DNA/rAd5-Gag. This may not be too
surprising, considering that LV-Gag and rAd5-Gag target dif-
ferent cell populations through distinct cellular receptors and are
likely to mediate different forms of antigen presentations.
IL-2TNF- cells represented the highest portion of CD4 T
cells in the DNA/LV-Gag and LV-Gag/LV-Gag groups, with
IFN-IL-2, IFN-TNF-, and IFN-IL-2TNF- Gag-
specific CD4 T cells at detectable levels. Several studies on the
SIV-macaque model revealed that prolonged survival of in-
fected monkeys was associated with the preservation of SIV-
specific CD4 T cells producing IFN-, IL-2, and TNF- (8, 40,
44). The frequency of CD4 T cells producing three cytokines
simultaneously was also positively related to protection against
Leishmania major infection (35). Furthermore, CD4 T cells
were reported to be indispensable for secondary CD8 T-cell
expansion, and the depletion of them during the priming phase
led to deficient development of functional CD8 T-cell memory
(41, 45). The role of CD4 T cells is particularly important in a
prime/boost vaccination, because CD4 T cells help establish-
ment of CD8 T-cell functionality and expansion in the boost
phase of immunization (46). Balanced CD8 and CD4 T-cell
responses are thought to be highly desirable for vaccine effec-
tiveness, and were suggested by Liu et al. to explain an efficient
priming by rAd26 vectors (8). This cytokine profile study reveals
that DNA/LV-Gag is very effective regimen to produce both
multifunctional CD8 and CD4 HIV-specific T cells in mice.
We further assessed the breadth of antigen recognition dis-
played by vector-induced T cells. Our experiments showed that
there were three peptide pools that elicited the most vigorous
responses for all three groups of mice given a prime/boost
regimen. Although the magnitude of DNA/rAd5-Gag response
to the three dominant peptide pools was the highest, there was
a greater diversification of immunogen recognition by the DNA/
LV-Gag and LV-Gag/LV-Gag regimens. We speculate that
through the DC targeting, the vaccination involved with LV-Gag
might load and present antigens more efficiently in the DCs,
allowing the generation of broader responses (38). Our poly-
functional study also supports the notion that this wider epitope
response might be the result of a better CD4 T-cell response.
In summary, we report an effort to evaluate an anti-HIV
vaccination involving a LV directed to DCs. We found that both
the DNA/LV-Gag and LV-Gag/LV-Gag vaccination regimens
elicited multifunctional CD4 and CD8 Gag-specific T cells,
and the DNA/LV-Gag method generated the highest frequen-
cies of CD4 and CD8 cells secreting three cytokines simul-
taneously. Homologous or heterologous immunization using
LV-Gag-induced T cells recognizing a wide range of Gag
epitopes. This study in mice demonstrates that this DC-targeted
LV is a promising vector system and should warrant further
investigations in NHP to continue the evaluation of its potential
for future human HIV/AIDS vaccine development.
Materials and Methods
Mice and Vaccination Procedure. Six- to eight-week-old female BALB/c mice
were purchased from Charles River Laboratories. All animal procedures were
performed in accordance with the guidelines set by the National Institutes of
Health and the University of Southern California on the Care and Use of
Animals. The details of immunization protocols are described in the SI Text.
Plasmid Construction and Vector Production. The plasmid encoding the DC-
targeted envelope SVGmu was constructed as described in ref. 23. FUWGag
was constructed by insertion of the cDNA of a HIV-1 subtype B Gag into the
lentiviral backbone plasmid FUW (34) downstream of the human ubiquitin C
promoter. The production of LV-Gag and rAd5-Gag vectors is described in the
SI Text.
Tetramer Staining and Intracellular Cytokine Staining (ICCS). The details of
tetramer staining, staining for phenotypic analysis, ICCS, andmultiparameter
ICCS are described in the SI Text.
Antibody ELISA and IFN- ELISPOTAssays.Antibody responseswere assessed by
ELISA using the method described before (see SI Text) (47). ELISPOT assays
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were performed for IFN- using a kit from Millipore according to the manu-
facturer’s instruction (see SI Text ).
Statistical Analysis. The significance of the difference between groups was
evaluated by analysis of variance followed by a one-tailed Student t test.
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